Legal Representation
Attorney
Maury M. Tepper, III
USPTO Deadlines
Next Deadline
2190 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2025-07-08)
Due Date
July 08, 2031
Grace Period Ends
January 08, 2032
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
16 events| Date | Code | Type | Description |
|---|---|---|---|
| Jul 8, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Jul 8, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| May 20, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| May 20, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION |
| May 14, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Apr 19, 2025 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Apr 19, 2025 | DOCK | D | ASSIGNED TO EXAMINER |
| Apr 4, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Apr 4, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Apr 4, 2025 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Apr 4, 2025 | ECDR | I | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
| Apr 4, 2025 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Mar 28, 2025 | MAFR | O | APPLICATION FILING RECEIPT MAILED |
| Mar 28, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Mar 25, 2025 | LIMI | I | LIMITATION FROM ORIGINAL APPLICATION ENTERED |
| Mar 13, 2025 | SDRC | M | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB |
Detailed Classifications
Class 005
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
Classification
International Classes
005